PPAR Signaling in Pain Management: A Survey

Abstract

The peroxisome proliferator-activated receptors (PPARs), especially PPAR, are vital in pain management due to their role in neural repair and inflammation modulation. This survey explores the therapeutic potential of PPAR agonists, particularly in treating neuropathic and inflammatory pain. PPAR agonists, such as pioglitazone and rosiglitazone, enhance neural differentiation and offer neuroprotection, making them promising for chemotherapy-induced neuropathic pain (CINP) and other chronic pain conditions. The anti-inflammatory and antioxidant properties of PPAR agonists, including natural compounds like magnolol, further extend their application to inflammatory pain management. The survey also highlights the interplay between PPAR signaling and metabolic disorders, suggesting that targeting these pathways could provide novel therapeutic approaches for pain and related metabolic conditions. The development of dual and pan-PPAR agonists, which activate multiple isoforms, is emphasized as a promising strategy to address the complex nature of chronic pain. Integrating PPAR agonists with other therapeutic agents could enhance efficacy, offering a multifaceted approach to pain management. Future research should focus on clinical trials and combination therapies to validate and expand the therapeutic use of PPAR agonists in pain management.

1 Introduction

1.1 Significance of PPAR Signaling in Pain Management

Peroxisome proliferator-activated receptors (PPARs), particularly PPAR, are crucial in pain management, presenting novel therapeutic opportunities. The PPAR signaling pathway facilitates the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, essential for neural repair post-injury [1]. This underscores the potential of PPAR agonists in aiding recovery from neuropathic pain, where nerve damage is prevalent.

Moreover, PPAR signaling's therapeutic implications extend to conditions such as chemotherapy-induced neuropathic pain (CINP), significantly affecting cancer patients' quality of life [2]. Integrating PPAR agonists into existing pain management regimens may alleviate the limitations of traditional therapies, which often provide only symptomatic relief and are accompanied by considerable side effects [3].

PPARs also modulate inflammation and oxidative stress, both critical in pain pathophysiology. The capacity of PPAR agonists to influence these pathways broadens their applicability in managing inflammatory pain conditions, particularly in metabolic disorders, where PPAR regulates processes linked to cardiovascular diseases [4]. The relationship between metabolic syndrome and chronic pain underscores the importance of PPAR signaling in developing holistic pain management strategies [5].

The significance of PPAR signaling in pain management is multifaceted, affecting therapeutic strategies through direct modulation of pain pathways and indirect benefits via metabolic regulation and neural repair. PPAR agonists emerge as promising candidates for addressing the complexities of chronic and neuropathic pain, especially in CINP, where conventional treatments often fall short. This relevance is heightened by the rising incidence of cancers treated with agents that can induce



Figure 1: chapter structure

CINP, necessitating innovative pain management strategies targeting underlying neuroinflammatory mechanisms [2, 3].

1.2 Potential of PPAR Agonists

The investigation of PPAR agonists in pain management reveals significant therapeutic potential, particularly for neuropathic and inflammatory pain. PPAR agonists, such as pioglitazone and rosiglitazone, are promising for treating CINP, providing not only symptomatic relief but also enhancing cancer treatment efficacy [2]. This dual action emphasizes the role of PPAR agonists in multifaceted pain management strategies.

Beyond neuropathic pain, PPAR agonists exhibit notable anti-inflammatory and antioxidant effects, as demonstrated by compounds like magnolol, which prevent liver damage through specific signaling pathways [6]. These properties are vital for managing inflammatory pain, where oxidative stress and inflammation are pivotal. The ability of PPAR agonists to modulate these pathways extends their therapeutic scope to conditions associated with metabolic syndrome, often linked to chronic pain [5].

Additionally, the integration of PPAR agonists with master modulators has been proposed to induce anakoinosis, or communicative reprogramming, in tumor tissues, highlighting their potential in oncology [7]. This suggests that PPAR agonists may not only provide direct analgesic effects but also alter disease progression through systemic modulation.

The benefits of PPAR agonists, particularly fibrates, contribute to cardiovascular health by improving lipid profiles and reducing cardiovascular risk factors, indirectly influencing pain management in metabolic health-related conditions [4]. This multifaceted approach positions PPAR agonists as

versatile agents capable of addressing the intricate interplay between metabolic disorders and chronic pain.

The promise of PPAR agonists in pain management primarily stems from their ability to regulate key biological pathways related to inflammation, oxidative stress, and metabolic processes. These agonists have shown efficacy in addressing chemotherapy-induced neuropathic pain by targeting mechanisms such as axonal transport disruptions and central nervous system inflammation, common in patients treated with agents like oxaliplatin and paclitaxel. Furthermore, PPAR agonists may enhance metabolic regulation, thereby improving overall patient quality of life and potentially alleviating severe side effects of cancer therapies [7, 2, 5, 4]. These attributes make them valuable candidates for developing comprehensive and effective pain management strategies, especially in chronic and complex pain conditions.

1.3 Structure of the Survey

This survey is structured to thoroughly explore the role of PPAR signaling in pain management, focusing on neuropathic and inflammatory pain. It begins with an **Introduction** that establishes the significance of PPAR pathways in pain modulation and the therapeutic potential of PPAR agonists. This is followed by a detailed **Background and Definitions** section, which outlines the PPAR signaling pathway, elaborates on various PPAR isoforms and their cellular roles, and defines key terms such as neuropathic pain, inflammatory pain, and chronic pain.

The **PPAR Signaling Pathway** section delves into the molecular mechanisms of PPAR signaling, examining the specific functions of different PPAR isoforms and their impact on cellular metabolism and inflammation. It highlights PPAR's role in neuroinflammation and the interaction between the PI3K/Nrf2/PPAR pathway and inflammation.

The **Neuropathic and Inflammatory Pain** section investigates the pathophysiological mechanisms underlying these pain types and discusses how PPAR signaling influences them, emphasizing PPAR's role in modulating pain pathways and reviewing current research while suggesting future directions.

The survey transitions to **PPAR Agonists in Pain Management**, providing a comprehensive analysis of the pharmacological potential of PPAR agonists. It evaluates their efficacy in alleviating neuropathic and inflammatory pain, particularly in the context of chemotherapy-induced neuropathic pain, a severe side effect of cancer treatments. The discussion also addresses physiological mechanisms underlying pain relief, current challenges in PPAR agonist therapies, and recent advancements, including the development of dual and pan-PPAR agonists that may enhance therapeutic outcomes [2, 5].

In the **Receptor Pharmacology and Chronic Pain** section, the focus shifts to integrating PPAR agonists with other therapeutic agents and exploring emerging therapeutic agents and novel candidates within receptor pharmacology that may benefit from PPAR agonist integration.

Finally, the paper concludes with a **Conclusion** that synthesizes key findings, reflects on the potential of PPAR signaling and agonists in pain management, and suggests future research directions and implications for clinical practice. This structured approach facilitates a comprehensive analysis of the diverse effects of PPAR signaling on pain management strategies, particularly concerning chemotherapy-induced neuropathic pain and its underlying mechanisms, thus enhancing our understanding of potential therapeutic applications and treatment outcome modulation [7, 8, 2, 3, 4].The following sections are organized as shown in Figure 1.

2 Background and Definitions

2.1 Overview of the PPAR Signaling Pathway

The peroxisome proliferator-activated receptor (PPAR) signaling pathway is crucial in regulating neurogenesis, lipid metabolism, and inflammation. PPARs, part of the ligand-inducible nuclear hormone receptor family, function as transcription factors modulating gene expression in response to specific ligands. The three isoforms—PPAR, PPAR/, and PPAR—are vital in processes such as metabolism, inflammation, and cell differentiation, with their activation significantly altering gene expression to affect cellular functions. This offers therapeutic potential for conditions like metabolic syndrome and cancer, with recent research focusing on optimizing PPAR agonist combinations to enhance efficacy and tackle challenges like drug resistance and tumor heterogeneity [9, 5, 7, 8, 4].

PPAR primarily influences lipid metabolism and inflammation, regulating genes involved in fatty acid oxidation and energy homeostasis, relevant to pain mechanisms where metabolic dysregulation exacerbates pain [4]. PPAR, extensively studied for its role in neurogenesis and tumor biology, promotes the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes when activated by ligands like 15d-PGJ2, released from M2 microglia, highlighting its significance in neural repair [1]. PPAR's involvement in tumor biology via nuclear receptor pathways suggests its potential in therapeutic strategies targeting tumor progression [7].

The interplay between PPAR signaling and metabolic syndromes is significant, as these pathways influence cancer progression and systemic metabolic homeostasis [8]. PPARs' regulation of gene expression linked to lipid metabolism and inflammation positions them as critical in understanding complex diseases' pathophysiology, including cancer and metabolic disorders.

2.2 Types of PPARs and Their Roles

PPARs comprise three isoforms—PPAR, PPAR/, and PPAR—each with distinct roles in cellular processes and metabolic and inflammatory pathway regulation. PPAR, mainly expressed in tissues with high fatty acid oxidation rates like the liver, heart, and skeletal muscle, regulates lipid metabolism, influencing fatty acid transport and oxidation. This function is essential for energy homeostasis and has therapeutic implications for hyperlipidemia and cardiovascular diseases [4]. Additionally, PPAR's modulation of inflammatory responses makes it a target for managing metabolic dysregulation-exacerbated inflammatory disorders [5].

PPAR/, though less studied, significantly impacts lipid metabolism and energy balance. It is ubiquitously expressed and regulates fatty acid oxidation in skeletal muscle and adipose tissue. Activation of PPAR/ enhances mitochondrial biogenesis and oxidative capacity, making it a promising target for metabolic syndrome and obesity-related disorders, particularly in ameliorating insulin resistance and dyslipidemia [4, 5]. Its role in promoting lipid catabolism and energy expenditure underscores its importance in metabolic homeostasis.

PPAR, the most extensively studied isoform, is crucial for adipogenesis and glucose homeostasis. Highly expressed in adipose tissue, it regulates insulin sensitivity and adipocyte differentiation. PPAR agonists, like thiazolidinediones, are used clinically for type 2 diabetes management due to their ability to enhance insulin sensitivity. Beyond metabolism, PPAR is involved in neurogenesis and inflammation, promoting neural repair by differentiating NSPCs into neurons and oligodendrocytes [1]. PPAR's anti-inflammatory properties benefit conditions characterized by chronic inflammation, including neurodegenerative diseases and cancer [7].

The diverse roles of PPAR isoforms in regulating cellular processes emphasize their critical importance in maintaining physiological homeostasis, particularly in metabolic regulation and cardiovascular health. Their unique mechanisms of action and tissue distribution position them as promising therapeutic targets for treating metabolic syndromes, cardiovascular diseases, and potentially cancer, with ongoing research into their modulation through synthetic and natural agonists and combination therapies [7, 8, 4, 5]. The ability of PPARs to modulate metabolic and inflammatory pathways offers promising avenues for treating various diseases, including metabolic disorders, inflammatory conditions, and neurodegenerative diseases.

2.3 Definitions of Key Pain Terms

Neuropathic pain is a chronic condition caused by direct injury or dysfunction of the nervous system, often inadequately addressed by current therapies that focus on symptomatic relief and may cause significant side effects [3]. A specific type of neuropathic pain is chemotherapy-induced neuropathic pain (CINP), resulting from the neurotoxic effects of anticancer treatments, significantly impacting patients' quality of life during chemotherapy [2].

Inflammatory pain, linked to tissue damage and the ensuing inflammatory response, involves immune system activation that releases pro-inflammatory cytokines and mediators, sensitizing nociceptors and intensifying pain perception. This mechanism is evident in neuropathic pain, where neuroinflammation plays a significant role. For instance, *Zingiber officinale* (ginger) extracts can alleviate neuropathic pain by inhibiting neuroinflammatory responses, suggesting a potential therapeutic avenue for managing immune activation-linked pain. In CINP, central nervous system inflammation

exacerbates symptoms, highlighting the complex interplay between immune responses and pain perception [1, 2, 3]. Inflammatory pain is commonly observed in conditions like arthritis, infection, and injury, where inflammation is central to the pathophysiology.

Chronic pain persists beyond the typical healing timeframe, usually lasting more than three to six months, and is often associated with various underlying conditions, including neuropathic pain due to nerve injury or chemotherapy-induced damage. This prolonged pain state can significantly affect quality of life and complicate treatment options, as current therapies often provide only symptomatic relief and can have substantial side effects. Understanding chronic pain mechanisms, including neuroinflammation, is crucial for developing more effective management strategies [7, 2, 3]. Chronic pain can result from unresolved acute pain, an ongoing pathological process, or a condition where pain is the primary symptom. It involves complex interactions among biological, psychological, and social factors, making effective management challenging. The persistence of pain can lead to functional impairment, psychological distress, and reduced quality of life, necessitating comprehensive and multidisciplinary approaches for management.

2.4 Relevance of PPAR Agonists in Receptor Pharmacology

PPAR agonists are pivotal in receptor pharmacology, particularly concerning their therapeutic implications for managing pain and metabolic disorders. These agonists selectively activate specific PPAR isoforms, a subset of nuclear hormone receptors that regulate gene expression in response to ligand binding, influencing physiological processes such as metabolism, inflammation, and cell differentiation. Their therapeutic potential, particularly in cancer and metabolic syndromes, is enhanced when combined with agents acting as 'master modulators,' facilitating tumor tissue reprogramming and promoting beneficial gene expression changes, including up-regulation of tumor suppressor genes [9, 7, 4, 5]. This modulation is crucial for regulating metabolic pathways, inflammation, and cellular differentiation, all integral to pain management strategies.

PPAR agonists primarily influence lipid metabolism and energy homeostasis by regulating genes associated with fatty acid oxidation, relevant in conditions like hyperlipidemia and cardiovascular diseases [4]. However, the complexity of metabolic pathways presents challenges in developing therapies that safely modulate PPAR activity without adverse effects, underscoring the need for precise targeting in receptor pharmacology.

The therapeutic implications of PPAR agonists extend beyond single isoform targeting. The development of dual and pan-PPAR agonists represents a promising approach in pain management, as these agents can activate multiple PPAR isoforms simultaneously, potentially offering synergistic benefits [5]. This strategy could enhance therapeutic efficacy by addressing the multifaceted nature of pain, which often involves overlapping metabolic and inflammatory pathways.

3 PPAR Signaling Pathway

3.1 Molecular Mechanisms of PPAR Signaling

The peroxisome proliferator-activated receptor (PPAR) signaling pathway involves intricate molecular mechanisms essential for lipid metabolism, inflammation, and cellular differentiation. PPARs, as ligand-activated nuclear receptors, function as transcription factors, regulating gene expression upon agonist binding. They form heterodimers with retinoid X receptors (RXRs) and bind to peroxisome proliferator response elements (PPREs) in target gene promoters, influencing transcriptional activity. This interaction is crucial for metabolic regulation and therapeutic strategies targeting conditions like metabolic syndrome and cancer, where altered gene expression can impact tumor behavior and treatment responses [7, 5].

As illustrated in Figure 2, the hierarchical structure of the PPAR signaling pathway emphasizes the molecular mechanisms, therapeutic implications, and different PPAR isoforms. The figure highlights key processes such as ligand binding, heterodimer formation, and transcriptional regulation, while also addressing the therapeutic implications for metabolic disorders, cancer treatment, and neuropathic pain. The PPAR isoforms covered are PPAR, PPAR/, and PPAR, each playing distinct roles in the signaling pathway.

Activation of PPAR signaling involves ligands, including natural fatty acids and synthetic agonists, binding to the receptor's ligand-binding domain, essential for metabolic regulation and therapeutic interventions in metabolic syndrome [8, 5]. This binding induces conformational changes in PPARs, facilitating coactivator recruitment or corepressor release, ultimately leading to transcriptional regulation of genes involved in metabolic and inflammatory pathways.

PPAR activation has shown anti-inflammatory and neuroprotective effects in pain management, especially in neuropathic pain contexts. For instance, Zingiber officinale extract (ZOE) administration in mice with peripheral neuropathy exhibited analgesic effects through modulation of PPAR signaling pathways [3]. This underscores the potential of PPAR agonists in alleviating pain by targeting inflammation and oxidative stress-related mechanisms.

PPARs, including PPAR, PPAR/, and PPAR, are integral in regulating lipid metabolism, influencing conditions like obesity, diabetes, and cardiovascular disease [8, 4]. PPAR activation enhances fatty acid oxidation and energy homeostasis, critical for metabolic balance and pain management in metabolic disorders. The capacity of PPARs to modulate these pathways highlights their therapeutic potential in addressing complex pain conditions with metabolic and inflammatory components.

The molecular mechanisms of PPAR signaling, through ligand-activated transcriptional regulation, significantly impact biological processes relevant to pain management. The therapeutic implications are substantial, offering promising avenues for targeted interventions aimed at alleviating neuropathic and inflammatory pain conditions, particularly through natural extracts like Zingiber officinale and novel pharmacological agents such as PPAR agonists for chemotherapy-induced neuropathic pain [2, 3].



Figure 2: This figure illustrates the hierarchical structure of the PPAR signaling pathway, highlighting the molecular mechanisms, therapeutic implications, and different PPAR isoforms. The molecular mechanisms include ligand binding, heterodimer formation, and transcriptional regulation. Therapeutic implications focus on metabolic disorders, cancer treatment, and neuropathic pain. The PPAR isoforms covered are PPAR, PPAR/, and PPAR.

3.2 PPAR Isoforms and Their Functions

PPARs consist of three isoforms: PPAR, PPAR/, and PPAR, each with distinct physiological roles. PPAR, primarily expressed in tissues with high fatty acid oxidation rates—such as the liver, heart, and skeletal muscle—regulates lipid metabolism by influencing the expression of genes involved in fatty acid transport and oxidation [4]. This function is vital for energy homeostasis and has therapeutic implications in hyperlipidemia and cardiovascular diseases, with its anti-inflammatory properties highlighting its potential in managing inflammatory disorders [5].

PPAR/, though less studied, is significant in lipid metabolism and energy balance, enhancing mitochondrial biogenesis and oxidative capacity, making it a potential target for metabolic syndrome and obesity-related disorders. Its role in promoting lipid catabolism underscores its importance in metabolic homeostasis [7, 4].

PPAR, the most extensively researched isoform, is crucial for adipogenesis and glucose homeostasis, primarily expressed in adipose tissue. It regulates insulin sensitivity and adipocyte differentiation, with agonists like thiazolidinediones used clinically for type 2 diabetes management due to their insulin-sensitizing effects. Beyond metabolism, PPAR is implicated in neurogenesis and inflammation, promoting the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, which

is vital for neural repair and neuroprotection [1]. Its anti-inflammatory properties are beneficial in chronic inflammatory conditions, including neurodegenerative diseases and cancer [7].

3.3 PPAR and Neuroinflammation

PPAR significantly modulates neuroinflammation, a key factor in neuropathic and inflammatory pain conditions. Neuroinflammation, characterized by glial cell activation—particularly microglia and astrocytes—leads to the release of pro-inflammatory cytokines that sensitize nociceptive pathways and amplify pain signals. M1 microglia create a pro-inflammatory environment that impedes the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, potentially leading to increased astrocyte formation and glial scar development, exacerbating pain sensitivity. Conversely, M2 microglia, activated through PPAR signaling, promote neurogenesis and oligodendrogenesis, indicating a complex interplay between microglial phenotypes in pain modulation and neuroinflammatory responses. Studies on Zingiber officinale extract suggest that targeting neuroinflammation could provide therapeutic avenues for alleviating neuropathic pain by inhibiting inflammatory processes [1, 3]. The anti-inflammatory properties of PPAR highlight its promise as a therapeutic target in these conditions.

PPAR activation suppresses pro-inflammatory cytokines, such as TNF-, IL-1, and IL-6, in activated microglia, thereby mitigating neuroinflammatory responses [1]. This effect is mediated through inhibition of the NF-B signaling pathway, a key regulator of inflammatory gene expression. By attenuating NF-B activation, PPAR reduces inflammatory mediator production, alleviating the inflammatory component of pain.

In addition to its anti-inflammatory effects, PPAR activation fosters neuroprotection and neural repair, crucial in neuropathic pain contexts where nerve damage is prevalent. PPAR agonists, including pioglitazone and rosiglitazone, enhance the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, contributing to neural repair and regeneration [1]. This capacity for supporting neural repair underscores the therapeutic potential of PPAR agonists in mitigating nerve injury effects and promoting recovery in neuropathic pain conditions.

Moreover, PPAR's role in modulating oxidative stress—an element contributing to neuroinflammation and pain—emphasizes its importance in pain management. By reducing oxidative stress and inflammation, PPAR activation can diminish pain pathway sensitization, providing analgesic effects. Incorporating PPAR agonists into pain management strategies represents a comprehensive approach to addressing the dual challenges of inflammatory and neurodegenerative pain mechanisms, particularly in chemotherapy-induced neuropathic pain, where traditional therapies often fall short. This multifaceted strategy not only tackles physiological changes associated with pain but also enhances patient quality of life amid rising cancer incidence and treatment-related complications [7, 2, 3].

The modulation of neuroinflammation by PPAR offers a promising therapeutic strategy for alleviating pain, especially in chemotherapy-induced neuropathic pain and other chronic inflammatory states characterized by nerve damage, where conventional treatments have shown limited efficacy and significant side effects [2, 3]. The ability of PPAR agonists to attenuate inflammatory responses and promote neural repair positions them as promising agents in developing comprehensive pain management strategies.

3.4 PI3K/Nrf2/PPAR Pathway and Inflammation

The PI3K/Nrf2/PPAR signaling pathway is critical in regulating inflammation, with significant implications for managing inflammatory pain conditions. This pathway, involving phosphoinositide 3-kinase (PI3K), nuclear factor erythroid 2-related factor 2 (Nrf2), and PPAR, plays a vital role in regulating oxidative stress and inflammatory responses. PI3K activates downstream signaling that enhances Nrf2-mediated antioxidant responses, while PPAR modulates gene expression related to metabolism and inflammation, collectively influencing cellular homeostasis and impacting disease processes like cancer and liver damage [5, 7, 6, 8, 4].

Activation of the PI3K pathway leads to the phosphorylation and activation of downstream signaling molecules involved in cell survival, proliferation, and metabolism. This pathway also activates Nrf2, a transcription factor regulating antioxidant response element (ARE)-driven gene expression. Nrf2 activation upregulates various antioxidant enzymes and cytoprotective proteins, such as HO-1 and

PPAR, which are critical in mitigating oxidative stress and its associated inflammatory responses, thus protecting against conditions like alcoholic liver damage and promoting neurogenesis from neural stem/progenitor cells [7, 1, 6, 8, 3].

As part of this signaling axis, PPAR further modulates inflammation through its transcriptional regulation of genes involved in lipid metabolism and anti-inflammatory responses. Integrating PPAR into the PI3K/Nrf2 pathway enhances anti-inflammatory and antioxidant effects, contributing to the attenuation of inflammatory processes. This interaction is particularly relevant in chronic inflammatory diseases, where oxidative stress and inflammation contribute to progression and severity, highlighting the need for targeted therapeutic strategies addressing these interconnected pathological features [7, 6, 8, 3, 4].

Recent studies have emphasized the potential of natural compounds like magnolol to activate the PI3K/Nrf2/PPAR signaling pathways while inhibiting the NLRP3 inflammasome, a key driver of inflammatory responses [6]. Magnolol's inhibition of the NLRP3 inflammasome suggests a novel therapeutic approach for reducing inflammation and oxidative stress, providing protective effects against inflammatory conditions.

The PI3K/Nrf2/PPAR signaling pathway is integral to modulating inflammation and oxidative stress, making it a promising target for therapeutic interventions aimed at alleviating inflammatory pain. Recent studies, including those on the analgesic effects of Zingiber officinale extract, highlight the importance of this pathway in mitigating neuroinflammation associated with neuropathic pain. Additionally, PPAR agonists have been proposed as potential therapeutic approaches for managing chemotherapy-induced neuropathic pain, further underscoring the relevance of this pathway in various pain conditions [2, 3, 8]. Exploring this pathway and its modulation by specific agonists or natural compounds could lead to innovative strategies for controlling inflammation and enhancing pain management.

In recent years, understanding the complex mechanisms underlying pain has become increasingly critical in the field of pain management. A significant aspect of this research involves elucidating the roles of various molecular pathways and their interactions. As illustrated in Figure 3, the hierarchical structure of neuropathic and inflammatory pain mechanisms is depicted, emphasizing the pivotal role of PPAR in pain modulation. This figure categorizes the pathophysiological mechanisms into distinct areas, including nervous system injury, chemotherapy-induced neuropathic pain, immune response, and neuroinflammation. Notably, it highlights PPAR's anti-inflammatory, neuroprotective, and metabolic regulatory effects, which are crucial for developing effective therapeutic strategies. Furthermore, the figure underscores future research directions that advocate for the exploration of PPAR agonists and combination therapies, thereby paving the way for innovative approaches to pain management.



Figure 3: This figure illustrates the hierarchical structure of neuropathic and inflammatory pain mechanisms, highlighting the role of PPAR in pain modulation and current research directions. It categorizes the pathophysiological mechanisms into nervous system injury, chemotherapy-induced neuropathic pain, immune response, and neuroinflammation, with a focus on PPAR's anti-inflammatory, neuroprotective, and metabolic regulatory effects. Future research directions emphasize the exploration of PPAR agonists and combination therapies.

4 Neuropathic and Inflammatory Pain

4.1 Pathophysiological Mechanisms of Neuropathic Pain

Neuropathic pain, arising from nervous system injury or dysfunction, is marked by persistent pain resistant to standard analgesics. Its pathophysiology involves complex interactions between peripheral and central nervous systems, where nerve damage induces maladaptive changes in pain signaling pathways. Chemotherapy-induced neuropathic pain (CINP) exemplifies this, with neurotoxic agents like platinum and taxanes causing peripheral nerve damage and altering sensory processing, leading to chronic pain [2]. PPARs, particularly PPAR, have gained attention for their role in modulating inflammation and oxidative stress, crucial in neuropathic pain mechanisms. PPAR activation suppresses pro-inflammatory cytokines and modulates oxidative stress pathways, alleviating inflammatory components of neuropathic pain [3].

The link between metabolic disorders and neuropathic pain highlights the significance of PPAR signaling. Conditions such as non-alcoholic fatty liver disease (NAFLD) can exacerbate neuropathic pain through systemic inflammation and metabolic imbalances [9]. PPARs regulate lipid metabolism and inflammatory pathways, connecting metabolic health to pain modulation. This connection is also evident in tumorigenesis, where metabolic disorders increase cancer risk and influence pain pathways through inflammation and cellular stress mechanisms [8]. The intricate relationship between neuropathic pain, inflammation, and metabolic processes, with PPAR signaling at the core, underscores the therapeutic potential of PPAR agonists in managing conditions like CINP. These agonists target inflammation, mitochondrial dysfunction, and ion channel activity, addressing chronic pain complexity and enhancing patient quality of life by reducing reliance on traditional therapies with significant side effects [7, 2, 3, 5].

4.2 Pathophysiological Mechanisms of Inflammatory Pain

Inflammatory pain, resulting from the immune response to tissue injury or infection, is characterized by immune cell activation and pro-inflammatory cytokine release, sensitizing nociceptors and amplifying pain perception. Neuroinflammation complicates this process, as seen in CINP, where central nervous system inflammation exacerbates pain and hinders recovery. Targeting pathways like PPAR signaling activated by M2 microglia offers therapeutic avenues for promoting neurogenesis and alleviating inflammation-associated pain [1, 2, 3]. The interplay between immune cells and nervous systems leads to the release of inflammatory mediators like prostaglandins, bradykinin, and cytokines (e.g., TNF- and IL-1), causing hyperalgesia and allodynia.

PPAR signaling is crucial in regulating inflammatory pain by modulating inflammation and cellular differentiation, influencing pain conditions' development and progression. PPAR promotes neurogenesis and oligodendrogenesis while modulating inflammatory responses, potentially alleviating pain in conditions such as CINP [1, 7, 8, 2, 4]. It exerts anti-inflammatory effects by downregulating pro-inflammatory cytokines and inhibiting the NF-B signaling pathway, reducing nociceptor sensitization and alleviating pain symptoms. Moreover, PPAR signaling affects neural stem/progenitor cell (NSPC) differentiation in inflammatory contexts. Inflammatory conditions can skew NSPCs toward astrocytic differentiation, influenced by PPAR activity [1]. Increased astrocyte differentiation can exacerbate central nervous system inflammatory responses, contributing to persistent inflammatory pain. By regulating NSPC differentiation and inflammatory pathways, PPAR emerges as a potential therapeutic target for managing inflammatory pain. The mechanisms underlying inflammatory pain involve complex interactions between immune responses and neural pathways, with PPAR signaling playing a crucial role in regulating these interactions. PPARs, part of the nuclear hormone receptor superfamily, influence various physiological processes, including inflammation and pain modulation, suggesting their potential as therapeutic targets in conditions like CINP, where central nervous system inflammation plays a significant role [7, 2, 3, 8]. The anti-inflammatory properties of PPAR and its influence on cellular differentiation emphasize its potential as a therapeutic target for alleviating inflammatory pain conditions.

4.3 Role of PPAR in Pain Modulation

PPAR is pivotal in modulating pain pathways through its anti-inflammatory and neuroprotective effects, crucial for both neuropathic and inflammatory pain contexts. Activation of PPAR downregu-

lates pro-inflammatory cytokines like TNF-, IL-1, and IL-6, key mediators in nociceptive pathway sensitization [1]. This action is mediated via NF-B signaling pathway inhibition, reducing inflammatory mediator production and alleviating pain's inflammatory component. In neuropathic pain, characterized by nerve damage and neuroinflammation, PPAR activation promotes neuroprotection and neural repair. PPAR agonists, such as pioglitazone and rosiglitazone, enhance the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, facilitating neural repair and regeneration [1]. This neurogenic potential is particularly valuable in conditions with central nerve injury, offering therapeutic avenues to mitigate nerve damage effects and promote recovery.

Additionally, PPAR modulates oxidative stress, a contributor to neuroinflammation and pain. By reducing oxidative stress, PPAR activation diminishes pain pathway sensitization, providing analgesic effects. Incorporating PPAR agonists into pain management strategies presents a comprehensive approach targeting both inflammatory and neurodegenerative mechanisms underlying pain, especially in CINP, where traditional treatments often fall short. These agonists not only modulate inflammatory responses but may also enhance neuroprotective pathways, improving patient outcomes and quality of life amid rising cancer incidence and its painful side effects [7, 2, 3]. The therapeutic potential of PPAR in pain modulation is further supported by its involvement in metabolic regulation. PPAR's influence on lipid metabolism and insulin sensitivity can indirectly affect pain pathways, particularly in conditions where metabolic dysregulation exacerbates pain [5]. This broad applicability of PPAR agonists in managing pain associated with metabolic disorders highlights its significant therapeutic potential. PPAR's multifaceted role in modulating inflammatory and oxidative stress pathways, fostering neurogenesis, and regulating metabolic processes underscores its promise in managing CINP and other chronic pain conditions. Its activation enhances the differentiation of neural stem/progenitor cells into neurons and oligodendrocytes, counteracting inflammation's adverse effects and promoting neural repair, thus offering a hopeful avenue for improving patient quality of life and treatment outcomes [7, 1, 2, 3]. These diverse effects position PPAR as a promising target for developing comprehensive strategies to alleviate chronic and complex pain conditions.

4.4 Current Research and Future Directions

Recent investigations into peroxisome proliferator-activated receptors (PPARs) have underscored their significant role in modulating pain pathways, particularly concerning neuropathic and inflammatory pain. The exploration of PPAR agonists, especially PPAR, has revealed promising therapeutic potential due to their anti-inflammatory and neuroprotective properties. Current research primarily focuses on the efficacy of PPAR agonists in animal pain models, indicating their ability to attenuate inflammatory responses and promote neural repair [5]. Despite these advancements, further research is essential to fully elucidate the therapeutic potential of PPAR agonists in clinical settings. Future studies should prioritize investigating dual and pan-PPAR agonists, which could activate multiple PPAR isoforms simultaneously, enhancing pain management strategies by addressing the multifaceted nature of pain involving overlapping metabolic and inflammatory pathways [5]. Additionally, larger phase 3 clinical trials that include diverse populations are critical to validate the efficacy and safety of PPAR agonists in pain management. These studies should utilize non-invasive techniques for monitoring treatment effects, ensuring comprehensive assessments of therapeutic outcomes. Furthermore, exploring combination therapies integrating PPAR agonists with other therapeutic agents could yield synergistic benefits, potentially improving treatment efficacy and patient outcomes [9].

5 PPAR Agonists in Pain Management

Category	Feature	Method
Challenges in PPAR Agonist Therapies	Therapeutic Strategy	ZOE[3]

Table 1: This table summarizes the challenges faced in the application of PPAR agonist therapies, highlighting the therapeutic strategies employed to address these issues. The method used, ZOE, is referenced to provide insights into overcoming the limitations associated with PPAR agonists in clinical settings.

The therapeutic potential of peroxisome proliferator-activated receptor (PPAR) agonists in pain management is underscored by their ability to modulate key inflammatory and metabolic pathways. This section delves into the pharmacological properties of PPAR agonists, focusing on their efficacy

across various pain conditions through innovative therapeutic strategies. Table 2 presents a concise overview of the therapeutic strategies and methods utilized to address the challenges in PPAR agonist therapies, as discussed in the preceding sections.

5.1 Pharmacological Potential of PPAR Agonists

PPAR agonists hold significant promise in pain management by influencing pathways related to inflammation, oxidative stress, and metabolism. PPAR agonists, in particular, exhibit anti-inflammatory and neuroprotective effects, enhancing neurogenesis and oligodendrogenesis in neural stem/progenitor cells (NSPCs) through M2 microglia supernatant, providing novel pain management strategies [1]. In chemotherapy-induced neuropathic pain (CINP), PPAR agonists mitigate oxidative stress and inflammation, addressing both symptoms and underlying neuropathic pain mechanisms [2]. Similarly, magnolol, a natural compound, reduces oxidative stress and inflammation, highlighting its potential in chronic inflammatory conditions [6]. Combining PPAR agonists with master modulators may enhance therapeutic efficacy, reduce toxicity, and overcome challenges like drug resistance [7].

PPAR agonists, particularly fibrates, are established in dyslipidemia management and cardiovascular risk reduction, providing insights into their mechanisms and clinical outcomes [4]. Their regulation of lipid metabolism and inflammatory pathways supports their potential in pain management, especially in conditions exacerbated by metabolic dysregulation. The interplay between PPARs and metabolic processes has revealed therapeutic strategies that leverage the multifaceted effects of PPAR agonists [8]. Moreover, PPAR agonists can mitigate adverse effects associated with current treatments for metabolic syndrome, enhancing their pharmacological value in pain management [5].

The unique pharmacological properties of PPAR agonists, including their modulation of inflammation and cellular signaling pathways, position them as promising candidates for innovative pain management strategies, particularly in addressing chemotherapy-induced neuropathic pain, a significant challenge in oncology [9, 7, 2, 5].

5.2 Efficacy in Neuropathic and Inflammatory Pain

PPAR agonists, particularly PPAR, are increasingly recognized for their effectiveness in neuropathic and inflammatory pain management. In chemotherapy-induced neuropathic pain (CINP), PPAR agonists significantly alleviate pain by modulating inflammatory and oxidative stress pathways [2]. In inflammatory pain, the activation of PI3K/Nrf2/PPAR signaling pathways is crucial for therapeutic efficacy. Liu et al. demonstrated magnolol's efficacy in preventing alcoholic liver damage via these pathways and inhibiting the NLRP3 inflammasome, suggesting similar mechanisms could treat inflammatory pain [6].

Exploring combinations of PPAR agonists with other therapeutic agents may enhance efficacy in pain management. The potential of PPAR agonists to influence tumor behavior when combined with other treatments underscores their versatility in complex pain conditions [7]. This combinatorial approach could yield synergistic benefits, particularly when single-agent therapies are inadequate.

Literature supports the effectiveness of PPAR agonists in alleviating neuropathic and inflammatory pain, highlighting their potential as a therapeutic option in pain management [5, 7, 2, 3, 4]. Their ability to target underlying biological pathways presents a promising avenue for developing more effective pain management strategies where conventional therapies are insufficient.

5.3 Challenges in PPAR Agonist Therapies

PPAR agonist therapies face significant challenges in enhancing efficacy and safety in clinical settings. A primary limitation is the need for further clinical validation of combinatorial therapies involving PPAR agonists. The complexity of tumor biology and variability in treatment responses necessitate comprehensive clinical trials to establish these approaches' effectiveness [7].

The efficacy of PPAR agonists as monotherapies is questioned, as they often require combination with other agents for optimal outcomes, particularly in managing metabolic syndrome [4]. This underscores the need for research into synergistic combinations that enhance efficacy without increasing adverse effects. Adverse effects like weight gain complicate their use in pain management, limiting long-term applicability and necessitating novel agents with improved safety profiles [5]. Small sample sizes and

short study durations in current research restrict robust conclusions on long-term efficacy and safety [9].

Current treatments for neuropathic pain, including those with PPAR agonists, often fail to address underlying causes and are associated with side effects limiting long-term use [3]. This highlights the need for innovative strategies targeting neuropathic pain's root causes while minimizing adverse effects. Addressing these challenges requires developing novel PPAR agonists with better safety profiles, conducting extensive clinical trials to validate combinatorial therapies, and implementing strategies to mitigate adverse effects. These efforts are essential for unlocking PPAR agonists' full therapeutic potential in pain management, particularly for chemotherapy-induced neuropathic pain (CINP), which poses significant challenges due to its debilitating effects on cancer patients. Understanding the mechanisms through which PPAR agonists operate can optimize their clinical use, potentially improving patient outcomes and quality of life amidst rising cancer incidence and treatment-related complications [7, 2, 5, 4].

5.4 Advancements in Dual and Pan-PPAR Agonists

Advancements in dual and pan-PPAR agonists have opened new avenues for enhancing pain management by targeting multiple PPAR isoforms simultaneously. These innovative agonists harness the combined effects of activating multiple PPAR isoforms, potentially enhancing therapeutic efficacy across a broader range of metabolic and inflammatory pathways associated with pain. This approach addresses the complex interplay of metabolic syndrome, obesity, and diabetes, which contribute to various cardiovascular and inflammatory diseases, improving treatment outcomes for related pain disorders [4, 5].

Dual PPAR agonists activating PPAR and PPAR simultaneously show promise in addressing lipid metabolism and inflammation interplay. PPAR activation enhances fatty acid oxidation and energy homeostasis, while PPAR provides anti-inflammatory and neuroprotective effects. This dual activation offers comprehensive benefits in managing conditions like metabolic syndrome and neuropathic pain, where metabolic dysregulation and inflammation are prevalent [4].

Pan-PPAR agonists, targeting all three PPAR isoforms (, /, and), represent an evolution in therapeutic design, maximizing therapeutic potential by exploiting each isoform's unique roles. PPAR/ inclusion in pan-agonists adds metabolic regulation, promoting lipid catabolism and energy expenditure, beneficial for treating obesity-related disorders and enhancing overall metabolic health. Comprehensive PPAR activation by pan-agonists could robustly modulate chronic pain mechanisms, including inflammatory and neuropathic pain [5].

Developing dual and pan-PPAR agonists is particularly relevant in receptor pharmacology, where integrating these agents with other therapeutic modalities could significantly enhance pain management strategies. By addressing pain pathophysiology's diverse components, these agonists offer potential to improve therapeutic outcomes and reduce limitations associated with single-isoform targeting [8].

Feature	Pharmacological Potential of PPAR Agonists	Efficacy in Neuropathic and Inflammatory Pain	Challenges in PPAR Agonist Therapies
Therapeutic Scope	Pain Management	Neuropathic Pain	Clinical Validation
Mechanism of Action	Anti-inflammatory Effects	Pathway Modulation	Combination Therapies
Challenges	Drug Resistance	Single-agent Inadequacy	Adverse Effects

Table 2: This table provides a comprehensive comparison of the pharmacological potential, efficacy, and challenges associated with PPAR agonists in pain management. It highlights the therapeutic scope and mechanisms of action of PPAR agonists, as well as the obstacles faced in their clinical application. The comparison underscores the need for innovative therapeutic strategies to enhance the efficacy and safety of PPAR agonist therapies.

6 Receptor Pharmacology and Chronic Pain

Advancements in receptor pharmacology are pivotal for understanding chronic pain mechanisms and developing targeted therapies. This section explores the integration of peroxisome proliferator-activated receptor gamma (PPAR) agonists with other therapeutic agents, emphasizing their capacity to synergistically modulate neuroinflammation and promote neural repair.

6.1 Integration of PPAR Agonists with Other Therapeutic Agents

Combining PPAR agonists with other therapeutic agents offers a promising avenue for enhancing pain management by modulating neuroinflammation and promoting neural repair. Activation of PPAR, facilitated by M2 microglia-induced differentiation of neural stem/progenitor cells (NSPCs) into neurons and oligodendrocytes, represents a novel approach to improving outcomes in neuropathic pain [1]. This strategy underscores the potential of integrating PPAR agonists with agents targeting complementary pathways to address multiple pain pathophysiology aspects.

Future research should focus on optimizing therapeutic combinations to identify master modulators that work synergistically with PPAR agonists, enhancing existing treatments and personalizing interventions based on patient responses [7]. Understanding the mechanisms of action is crucial for effectively deploying these combinations clinically.

Selective PPAR modulators with fewer side effects are also critical, complementing PPAR agonists by targeting metabolic aspects of pain syndromes. Dual and pan-PPAR agonists show promise in addressing metabolic syndrome components often linked with chronic pain [4]. Targeting a broader range of PPAR isoforms may yield comprehensive benefits in managing complex pain conditions characterized by metabolic and inflammatory dysregulation.

Integrating PPAR agonists with various therapeutic agents presents an innovative pain management strategy, leveraging PPARs' roles in inflammation regulation, metabolism, and neural repair. This approach is particularly relevant for chemotherapy-induced neuropathic pain, where PPAR agonists can alleviate treatment-related side effects, improving patient quality of life and adherence to cancer therapies. Combining PPAR agonists with other regulatory agents may enhance therapeutic outcomes by facilitating gene expression modulation and promoting tissue communication, leading to more effective management of complex pain syndromes and associated metabolic disturbances [5, 7, 8, 2, 4]. This strategy has the potential to improve pain management protocols, offering personalized and effective solutions for chronic and neuropathic pain patients.

6.2 Emerging Therapeutic Agents and Their Potential

Exploring new therapeutic agents in receptor pharmacology holds significant promise for advancing chronic pain management, particularly through developing novel PPAR agonists. Understanding these agonists' mechanisms in conditions like chemotherapy-induced neuropathic pain (CINP) is crucial for optimizing their therapeutic potential in clinical settings [2]. This involves delineating the pathways through which these agents exert their effects and identifying ways to enhance efficacy while minimizing adverse effects.

In addition to novel PPAR agonists, natural compounds like Zingiber officinale extract (ZOE) are gaining attention for their analgesic properties in neuropathic pain models. Future research should prioritize long-term investigations of ZOE in diverse neuropathic pain models to assess its efficacy and safety in clinical applications [3]. Such studies are essential for translating preclinical findings into therapeutic benefits for patients suffering from chronic pain.

Developing new PPAR agonists with improved safety profiles is a critical focus area, as these compounds may effectively manage metabolic syndrome and mitigate the risk of associated cardiovascular diseases exacerbated by rising obesity and diabetes rates globally [4, 5]. Addressing the limitations of existing therapies, such as side effects and limited efficacy, these novel agents could enhance therapeutic options for chronic pain management. Integrating these emerging agents into comprehensive pain management strategies could significantly improve patient outcomes, providing more effective and tailored interventions for chronic pain conditions.

The advancement of new therapeutic agents in receptor pharmacology is poised to transform chronic pain management. By focusing on the development and characterization of novel PPAR agonists and investigating the analgesic properties of natural compounds like Zingiber officinale Roscoe extract (ZOE), future research has the potential to yield innovative and effective treatments for chronic pain. This approach is particularly crucial given the limitations of current therapies for chemotherapy-induced neuropathic pain, which often present significant side effects and inadequate efficacy. The mechanisms underlying neuropathic pain, including neuroinflammation and central neurotoxicity, underscore the pressing need for safer and more effective pharmacological options [2, 3].

6.3 Novel Therapeutic Candidates

Identifying novel therapeutic candidates within receptor pharmacology that could synergize with PPAR agonists is an area of increasing interest for developing innovative pain management strategies. Exploring dual and pan-PPAR agonists exemplifies the potential of targeting multiple PPAR isoforms to achieve synergistic effects in modulating metabolic and inflammatory pathways central to chronic pain pathophysiology [5].

One promising avenue involves natural compounds such as magnolol, which has shown efficacy in activating the PI3K/Nrf2/PPAR signaling pathways while inhibiting the NLRP3 inflammasome, thereby reducing inflammation and oxidative stress [6]. Integrating such compounds with PPAR agonists could enhance their therapeutic potential, providing a multifaceted approach to managing inflammatory pain.

Additionally, combining PPAR agonists with master modulators in oncological contexts has been proposed to induce anakoinosis, or communicative reprogramming, in tumor tissues [7]. Similar strategies could be applied to pain management, where reprogramming cellular responses may alleviate pain symptoms and improve treatment outcomes.

The development of selective PPAR modulators that minimize adverse effects while maximizing therapeutic efficacy is crucial. This includes creating agents that specifically target PPAR isoforms involved in lipid metabolism and inflammation, offering potential benefits in conditions where metabolic dysregulation contributes to pain [4].

Identifying and integrating novel therapeutic candidates, particularly PPAR agonists, could significantly enhance pharmacological strategies for pain management, especially for conditions like chemotherapy-induced neuropathic pain (CINP), which currently lacks effective treatments. This approach could improve patient quality of life and address underlying pathophysiological mechanisms associated with pain, such as inflammation and neurotoxicity, thereby transforming existing paradigms in receptor pharmacology [9, 5, 2, 3, 4]. Leveraging the diverse mechanisms of action of these agents, future research can pave the way for more effective and comprehensive strategies for alleviating chronic and complex pain conditions.

7 Conclusion

The exploration of peroxisome proliferator-activated receptor (PPAR) signaling underscores its pivotal role in modulating neuropathic and inflammatory pain pathways. PPAR emerges as a significant factor in promoting neural repair, offering novel avenues for addressing neuroinflammation and associated pain conditions. The ability of PPAR agonists to support neurogenesis and exert anti-inflammatory effects suggests their transformative potential in refining current pain management approaches. Additionally, the interplay between PPAR signaling and metabolic disorders is instrumental in the progression of diseases like cancer, where metabolic imbalances exacerbate clinical outcomes. This connection highlights the potential of targeting PPAR pathways as a strategic intervention, extending its impact beyond pain management to include metabolic and oncological contexts. Future research should focus on developing dual and pan-PPAR agonists that can simultaneously engage multiple isoforms, effectively navigating the complex interactions between metabolic and inflammatory pathways in chronic pain. Moreover, the integration of PPAR agonists with other therapeutic modalities could enhance treatment efficacy, fostering the development of more comprehensive and individualized pain management strategies.

References

[1] Jichao Yuan, Hongfei Ge, Wei Liu, Haitao Zhu, Yaxing Chen, Xuan Zhang, Yang Yang, Yi Yin, Weixiang Chen, Wanjiang Wu, et al. M2 microglia promotes neurogenesis and oligodendrogenesis from neural stem/progenitor cells via the pparγ signaling pathway. *Oncotarget*, 8(12):19855, 2017.

[2] Nara Lins Meira Quintão, José Roberto Santin, Luis Carlos Stoeberl, Thiago Patrício Corrêa, Jéssica Melato, and Robson Costa. Pharmacological treatment of chemotherapy-induced neuropathic pain: Pparγ agonists as a promising tool. *Frontiers in neuroscience*, 13:907, 2019.

[3] Vittoria Borgonetti, Paolo Governa, Marco Biagi, Federica Pellati, and Nicoletta Galeotti. Zingiber officinale roscoe rhizome extract alleviates neuropathic pain by inhibiting neuroinflammation in mice. *Phytomedicine*, 78:153307, 2020.

[4] Lu Han, Wen-Jun Shen, Stefanie Bittner, Fredric B Kraemer, and Salman Azhar. Ppars: regulators of metabolism and as therapeutic targets in cardiovascular disease. part i: Ppar-α. *Future cardiology*, 13(3):259–278, 2017.

[5] Chek Kun Tan, Yan Zhuang, and Walter Wahli. Synthetic and natural peroxisome proliferator-activated receptor (ppar) agonists as candidates for the therapy of the metabolic syndrome. *Expert opinion on therapeutic targets*, 21(3):333–348, 2017.

[6] Xiao Liu, Yanan Wang, Di Wu, Shuangqiu Li, Chaoqun Wang, Zhen Han, Jingjing Wang, Kai Wang, Zhengtao Yang, and Zhengkai Wei. Magnolol prevents acute alcoholic liver damage by activating pi3k/nrf2/pparγ and inhibiting nlrp3 signaling pathway. *Frontiers in pharmacology*, 10:1459, 2019.

[7] Daniel Heudobler, Michael Rechenmacher, Florian Lüke, Martin Vogelhuber, Tobias Pukrop, Wolfgang Herr, Lina Ghibelli, Christopher Gerner, and Albrecht Reichle. Peroxisome proliferator-activated receptors (ppar) γ agonists as master modulators of tumor tissue. *International Journal of Molecular Sciences*, 19(11):3540, 2018.

[8] Daniele Fanale, Valeria Amodeo, and Stefano Caruso. The interplay between metabolism, ppar signaling pathway, and cancer. *PPAR research*, 2017:1830626, 2017.

[9] Alessandro Mantovani, Christopher D Byrne, and Giovanni Targher. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. *The lancet Gastroenterology & hepatology*, 7(4):367–378, 2022.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.